Key Takeaways
- Flat topline, margin reset: Revenue was flat YoY as a ~10% decline in specialty chemical realizations offset 30%+ volume-led ibuprofen growth. Gross margin expanded 500 bps YoY from raw material optimization, but EBITDA margin guidance stayed at a sober 15%–17%.
- Ibuprofen is the engine: The plant ran at 85%–90% capacity (vs 65%–75% a year ago) on sustained demand, and management expects that rate to hold for the full year. Prices have bottomed out.
- Non-ibuprofen APIs are the growth bet: The segment grew only ~10% YoY and carries single-digit EBITDA margins today, but management targets ₹500–550 crore revenue this year and double-digit margins once exports to regulated markets begin in 2–3 quarters.
- Backward integration moat is building: The new 25,000 TPA acetic anhydride plant and 100% backward integration in paracetamol (para-aminophenol plus acetic anhydride) give cost and reliability advantages that management claims no competitor matches.
- What to watch next quarter: Whether non-ibuprofen export approvals convert to orders on the 2–3 quarter timeline, the pace of paracetamol capacity expansion decisions, and any stabilization in specialty chemical realizations.
Topline: Flat Revenue, Shifting Mix
- Specialty chemicals dragged the headline: Sales declined ~10% YoY entirely from lower realizations on ethyl acetate and acetic anhydride, which tracked raw material costs down. Volumes held steady.
- Ibuprofen volume compensated: The pharma segment grew 30%+ YoY on volume, with the ibuprofen plant running at 85%–90% utilization. Management called demand sustainable and noted prices bottomed out in mid-FY23.
- Non-ibuprofen APIs muted but building: ~10% YoY growth was held back by sharp price drops on one or two products in Q1, though quantities are rising. European and Korean regulatory approvals are in hand, and customer validation is underway.
- Acetic anhydride adds a new topline stream: 40% of the newly commissioned plant's output goes to the merchant market, expected to contribute ~₹70 crore this year and peak at ~₹125 crore.
Mahajan: "This development is under the process already and it took maybe two quarters or three quarters, will start getting benefits from export markets probably in 8 to 9 months."
Margins: Gross Margin Up, EBITDA Guarded
- Gross margin jumped 500 bps YoY from raw material cost optimization, and management considers the improvement sustainable. A 50 bps QoQ dip from Q4 was attributed to higher-cost inventory clearing while finished prices had already softened; a small residual impact may bleed into one month of Q2.
- Employee cost spiked on one-timers: Q1 employee cost of ₹54 crore included variable pay from the prior financial year plus annual increments. The run-rate should settle around ₹48 crore going forward, with the incremental amount phasing proportionately through Q2–Q4. Headcount rose by ~400 to 2,725.
- Specialty chemical EBIT margins stuck low: Management expects the segment to stay in the 5%–6% range for the full year, with only minor improvement possible.
- Non-ibuprofen API margins are single-digit today: The path to double-digit margins (at par with ibuprofen) runs through capacity enhancement, full utilization, and export market entry, a journey management frames as 2–3 quarters away.
Singh: "We cannot comment that we will be achieving the 20%–22% EBITDA margin in this fiscal year or the next fiscal year, but I think something around 15% to 17% is sustainable."
Non-Ibuprofen APIs: The Next Leg
- The revenue bridge to FY25: Non-ibuprofen APIs currently contribute ~35% of pharma segment revenue. Management targets 50% by FY25, with FY24 revenue expected above ₹500–550 crore, implying ~20%–25% YoY growth for the next two years.
- Export unlocks are in motion: European and Korean approvals are secured; US FDA approval is awaited (DMF already filed). Customer validation for regulated markets is under process, and management expects incremental business to materialize in 2–3 quarters.
- China registration underway: Ibuprofen is already in the registration process with China's NMPA; paracetamol and Metformin are also under registration.
- The margin story is back-end loaded: Current single-digit EBITDA margins should move to double digits once exports to Europe begin and capacity utilization rises, per management's expectation of reaching parity with ibuprofen margins.
Mahajan: "As of now, you can say single digit EBITDA margin as of now, but with the capacity enhancement with full utilization and getting the export market, we hope for at par with the ibuprofen margins."
Backward Integration & Capacity
- Acetic anhydride plant is live and saving cost: The 25,000 TPA plant commissioned mid-June 2023 was running at ~80% capacity by the call date. Captive consumption provides reliability, supply continuity, and market-price-linked savings, though management declined to quantify the exact benefit.
- Paracetamol: 100% backward integrated, small base: IOL started at low capacity but is fully integrated with in-house para-aminophenol and acetic anhydride. Management stated no other company is 100% backward integrated in paracetamol. A capacity expansion decision depends on market response and approvals, with more clarity expected by end-Q2 or Q3.
- Ethyl acetate recertified for Europe: The product is already exported to the Middle East and Africa; European recertification opens a new regulated market. Some debottlenecking capacity expansion was completed last fiscal year.
- DMF/CEP filings stack up: 12 API DMFs and CEPs for 5 products have been filed, and a CEP approval for paracetamol was recently received.
Mahajan: "I think that IOL is the only company which is 100% backward integrated with para-aminophenol and Acetic anhydride. We think no other company is 100% backward integrated."
Capital Allocation & Returns
- FY24 CAPEX set at ~₹250 crore, funded entirely from internal accruals with no debt. Management declined to split this into maintenance vs growth, calling it premature to discuss growth CAPEX specifics until the next or third quarter.
- ROE is ~9% today with no internal target disclosed. Management offered only a directional hope for improvement as exports grow.
- New product development is in R&D: Shortlisted products are under evaluation for viability, market response, economies of scale, and backward integration potential. An announcement will follow board approval, with no timeline given.
Singh: "We are having certain shortlisted products. The R&D is continuously working on all these products and considering the viability and the market responses and the economies of scale, we will be coming out with the appropriate announcement after everything is finalized."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Ibuprofen capacity utilization | 85%–90% sustained | Full year FY24 |
| Non-ibuprofen API revenue | More than ₹500–550 crore | FY24 |
| Non-ibuprofen API growth rate | ~20%–25% YoY | Next 2 years, then re-analyze |
| Non-ibuprofen API margin improvement | Double-digit EBITDA (at par with ibuprofen) | 2–3 quarters, when Europe exports begin |
| Export market benefits | Incremental business from Europe and regulated markets | 2–3 quarters (8–9 months) |
| Acetic anhydride merchant revenue | ~₹70 crore, peaking at ~₹125 crore | FY24 / peak thereafter |
| Specialty chemical EBIT margin | 5%–6% range | Full year FY24 |
| Sustainable EBITDA margin | 15%–17% | Ongoing; 20%–22% not committed for FY24 or FY25 |
| CAPEX | ~₹250 crore, internally funded, no debt | FY24 |
| Paracetamol capacity expansion decision | Clarity expected | End-Q2 or Q3 FY24 |
| New product announcements | After R&D finalization and board approval | No date |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Total income | ₹570 cr, flat YoY |
| EBITDA | ₹79.9 cr, up 30.6% YoY from ₹61 cr; ₹105 cr in Q4 FY23 |
| EBITDA margin | 14.0%, improved 330 bps YoY from 10.7% |
| Net profit | ₹46.2 cr, up from ₹34.9 cr YoY; ₹65.3 cr in Q4 FY23 |
| EBIT margin – Pharmaceutical segment | 14.3% |
| EBIT margin – Specialty Chemical segment | 4.7% |
| Ibuprofen capacity utilization | 85%–90%, up from 65%–75% in June 22 |
| Ibuprofen export split | ~34% of ibuprofen revenue |
| Non-ibuprofen API revenue target FY24 | ₹500–550 cr, up from ~₹380 cr in FY23 |
| Non-ibuprofen API export split | ~15%–20% export, ~80%–85% domestic |
| Paracetamol capacity utilization | ~90% |
| Acetic anhydride plant capacity utilization | ~80%, commissioned mid-June 2023; ~60% captive, ~40% merchant |
| Acetic anhydride merchant revenue target FY24 | ₹70 cr, peak potential ~₹125 cr |
| CAPEX planned for FY24 | ~₹250 cr, funded through internal accruals |
| Net cash | ₹260 cr as of 30th June 2023 |
| Employee count | 2,725 as of 30th June 2023, up from ~2,300 in March 2023 |